UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.
Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depre
